Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Active not recruiting 4Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1CNS 1

Conditions

Meningioma 1Leukemia, Myeloid, Acute 1

Interventions

Specimen Handling 198Magnetic Resonance Spectroscopy 160pembrolizumab 141Carboplatin 117Biopsy 111Cyclophosphamide 93Cisplatin 93Paclitaxel 75Bevacizumab 61Gemcitabine 60Nivolumab 57fludarabine 53Radiotherapy 50Fluorouracil 49Pemetrexed 46Oxaliplatin 43Dexamethasone 43venetoclax 42Rituximab 41Leucovorin 41Doxorubicin 41durvalumab 40Docetaxel 40Capecitabine 39Radiation 37atezolizumab 35Prednisone 32Injections 31Fulvestrant 31Standard of Care 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Tablets × 30 days × Clear all
NCT06275919 2026-05-13

MIRAGE

Istituto Oncologico Veneto IRCCS

Phase 2 Recruiting
104 enrolled
CNS

Meningioma

NCT05907057 2026-05-08

An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.

Servier

Phase 3 Recruiting
245 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡